NCT01340898View on ClinicalTrials.gov

Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers

PHASE3CompletedINTERVENTIONAL
Enrollment

753

Participants

Timeline

Start Date

January 27, 2012

Primary Completion Date

August 4, 2014

Study Completion Date

October 19, 2015

Conditions
Meningococcal Infection
Interventions
BIOLOGICAL

Meningococcal vaccine GSK 134612

Intramuscular injection

BIOLOGICAL

SynflorixTM

Intramuscular injection

BIOLOGICAL

Infanrix-IPV/HiberixTM

Intramuscular injection

Trial Locations (2)

34000

GSK Investigational Site, Durango

1107-2020

GSK Investigational Site, Beirut

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01340898 - Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers | Biotech Hunter | Biotech Hunter